Body weight is a robust predictor of clinical progression in Huntington disease.
about
Overlap between age-at-onset and disease-progression determinants in Huntington disease.Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.Bioenergetics in fibroblasts of patients with Huntington disease are associated with age at onset
P2860
Body weight is a robust predictor of clinical progression in Huntington disease.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Body weight is a robust predictor of clinical progression in Huntington disease.
@en
type
label
Body weight is a robust predictor of clinical progression in Huntington disease.
@en
prefLabel
Body weight is a robust predictor of clinical progression in Huntington disease.
@en
P2093
P2860
P356
P1433
P1476
Body weight is a robust predictor of clinical progression in Huntington disease.
@en
P2093
G Bernhard Landwehrmeyer
Jorien M M van der Burg
N Ahmad Aziz
Sarah L Gardiner
P2860
P356
10.1002/ANA.25007
P577
2017-08-05T00:00:00Z